Persistence of dormant cancer cells that have resisted chemotherapy is a major barrier to curing ovarian cancer. Our group has developed the first inducible model for tumor dormancy in ovarian cancer using human ovarian cancer xenografts and has discovered a potential link between tumor dormancy and autophagy. Prolonged autophagy can induce cell death, whereas transient autophagy facilitates cell survival. We have found that ARHI (DIRAS3) - an imprinted tumor suppressor gene encoding a 26 kD GTPase homologous to Ras but with an opposite function - is required for autophagy in normal and malignant ovarian epithelial cells. ARHI participates directly in autophagosome formation, upregulating Atg4 and co-localizing in the autophagic vesicle membrane with MAP-LC3-II. ARHI also inhibits signaling through Class I PI3 kinase, ultimately decreasing the activity of mTOR, a known stimulus for the induction of autophagy. ARHI is downregulated in >60% of ovarian cancers. Re-expression of ARHI in ovarian cancer cells blocks proliferation by upregulating p21 and p27 and induces autophagic cell death in culture. In xenografts, re-expression of ARHI also blocks growth and induces autophagy, but cancer cells survive for months, remaining dormant and growing promptly when ARHI levels are subsequently reduced. Interestingly, growth factors (IGF-1, VEGF) and cytokines (IL-8) that are found in the xenograft microenvironment can rescue cancer cells from autophagic death in culture, block development of autophagy and partially reverse changes that occur in cell signaling during the induction of autophagy. Inhibition of autophagy with chloroquine inhibits subsequent growth of dormant cancer cells, but the precise relationship of autophagy and tumor dormancy remains to be defined. Other molecular abnormalities that occur frequently in ovarian cancers can regulate autophagy, including the overexpression of Rab25, but the interaction between ARHI and Rab25 has not been explored.
In Aim 1 we will define the role of ARHI in autophagic vesicle formation, testing the hypothesis that ARHI associates directly with nucleating autophagic vesicles through lipid-lipid interactions, inducing Atg4 through FoxO3a to cleave MAP-LC3, facilitating vesicle membrane elongation.
In Aim 2 we will explore the interaction of ARHI and Rab25 in regulating autophagy in ovarian cancer cells, testing the hypothesis that ARHI induces autophagy by inhibiting PI3 kinase activation, upregulating TSC1/2 and downregulating pmTOR, whereas Rab25 blocks ARHI-induced autophagy by activating Akt directly and increasing pmTOR activity. We also will determine whether expression of ARHI is associated with prolonged disease free survival, while expression of Rab25 will be associated with decreased progression free survival in ovarian cancer.
In Aim 3 we will determine requirements for ARHI-induced dormancy in xenografts, testing the hypotheses that: 1) dormancy depends critically on the induction of autophagy;2) survival of dormant autophagic cells in vivo requires permissive levels of VEGF, IL-8 and IGF-1;and 3) the accumulation of high levels of VEGF, IL-8 IGF-1 render ovarian cancer cells resistant to cell cycle arrest, autophagy and tumor dormancy. Further, we will seek autophagic cells that express ARHI in second look surgical specimens from women with ovarian cancer. If blocking VEGF, IGF-1 and IL-8 eliminates autophagic dormant ovarian cancer cells in xenografts, early translation to clinical trials should be feasible.

Public Health Relevance

The persistence of dormant cancer cells that have resisted chemotherapy is the major barrier to curing ovarian cancer. These studies will test a novel strategy to eliminate dormant ovarian cancer cells by blocking factors required for their survival. If successful, early translation to clinical trials should be feasible.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA135354-04
Application #
8286165
Study Section
Tumor Cell Biology Study Section (TCB)
Program Officer
Salnikow, Konstantin
Project Start
2009-07-17
Project End
2014-06-30
Budget Start
2012-07-01
Budget End
2014-06-30
Support Year
4
Fiscal Year
2012
Total Cost
$306,953
Indirect Cost
$107,633
Name
University of Texas MD Anderson Cancer Center
Department
Miscellaneous
Type
Other Domestic Higher Education
DUNS #
800772139
City
Houston
State
TX
Country
United States
Zip Code
77030
Yang, Hailing; Das, Partha; Yu, Yinhua et al. (2016) NDN is an imprinted tumor suppressor gene that is downregulated in ovarian cancers through genetic and epigenetic mechanisms. Oncotarget 7:3018-32
Ornelas, Argentina; McCullough, Christopher R; Lu, Zhen et al. (2016) Induction of autophagy by ARHI (DIRAS3) alters fundamental metabolic pathways in ovarian cancer models. BMC Cancer 16:824
Washington, M N; Suh, G; Orozco, A F et al. (2015) ARHI (DIRAS3)-mediated autophagy-associated cell death enhances chemosensitivity to cisplatin in ovarian cancer cell lines and xenografts. Cell Death Dis 6:e1836
Lu, Zhen; Baquero, Maria T; Yang, Hailing et al. (2014) DIRAS3 regulates the autophagosome initiation complex in dormant ovarian cancer cells. Autophagy 10:1071-92
Lu, Z; Yang, H; Sutton, M N et al. (2014) ARHI (DIRAS3) induces autophagy in ovarian cancer cells by downregulating the epidermal growth factor receptor, inhibiting PI3K and Ras/MAP signaling and activating the FOXo3a-mediated induction of Rab7. Cell Death Differ 21:1275-89
Simmons, Archana R; Baggerly, Keith; Bast Jr, Robert C (2013) The emerging role of HE4 in the evaluation of epithelial ovarian and endometrial carcinomas. Oncology (Williston Park) 27:548-56
Lyu, Tianjiao; Jia, Nan; Wang, Jieyu et al. (2013) Expression and epigenetic regulation of angiogenesis-related factors during dormancy and recurrent growth of ovarian carcinoma. Epigenetics 8:1330-46
Lu, Zhen; Bast Jr, Robert C (2013) The tumor suppressor gene ARHI (DIRAS3) inhibits ovarian cancer cell migration through multiple mechanisms. Cell Adh Migr 7:232-6
Badgwell, D B; Lu, Z; Le, K et al. (2012) The tumor-suppressor gene ARHI (DIRAS3) suppresses ovarian cancer cell migration through inhibition of the Stat3 and FAK/Rho signaling pathways. Oncogene 31:68-79
Romero, Ignacio; Bast Jr, Robert C (2012) Minireview: human ovarian cancer: biology, current management, and paths to personalizing therapy. Endocrinology 153:1593-602

Showing the most recent 10 out of 12 publications